Literature DB >> 14969052

Autoantibodies in early arthritis: advances in diagnosis and prognostication.

W Hueber1, P J Utz, W H Robinson.   

Abstract

Several excellent reviews have recently been published on the significance of autoantibodies in rheumatoid arthritis (RA) (1-4). Here we: (i) review selected longitudinal studies examining the predictive utility of autoantibodies in early arthritis and early RA cohorts; (ii) assess the relevance of autoantibodies as an independent parameter for prediction and prognostication of RA; and (iii) describe the potential of multiplex autoantibody assays, including miniaturized, high-throughput microarray technology, to improve diagnosis and prognostication in recent-onset synovitis/early arthritis patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14969052

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  11 in total

1.  Conference report--protein microarrays in cancer and autoimmunity: tiny spots light up highlights of the ABRF 2004--integrating technologies in proteomics and genomics; February 28-March 2, 2004; Portland, Oregon.

Authors:  Sara M Mariani
Journal:  MedGenMed       Date:  2004-04-09

Review 2.  [Early diagnosis of chronic systemic inflammatory disorders].

Authors:  B Hellmich; F Merkel; M Weber; W L Gross
Journal:  Internist (Berl)       Date:  2005-04       Impact factor: 0.743

3.  [Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)].

Authors:  Klaus P Machold; Hans Peter Brezinsek; Burkhard F Leeb; Stephan Pflugbeil; Franz Rainer; Franz Singer; Martin Skoumal; Tanja A Stamm; Manfred Herold
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

4.  Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis.

Authors:  Jeremy Sokolove; Dannette S Johnson; Lauren J Lahey; Catriona A Wagner; Danye Cheng; Geoffrey M Thiele; Kaleb Michaud; Harlan Sayles; Andreas M Reimold; Liron Caplan; Grant W Cannon; Gail Kerr; Ted R Mikuls; William H Robinson
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

5.  Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines.

Authors:  Wolfgang Hueber; Beren H Tomooka; Xiaoyan Zhao; Brian A Kidd; Jan W Drijfhout; James F Fries; Walther J van Venrooij; Allan L Metzger; Mark C Genovese; William H Robinson
Journal:  Ann Rheum Dis       Date:  2006-08-10       Impact factor: 19.103

Review 6.  Pre-RA: Can early diagnosis lead to prevention?

Authors:  Salina Haville; Kevin D Deane
Journal:  Best Pract Res Clin Rheumatol       Date:  2022-01-03       Impact factor: 4.098

Review 7.  Diagnostic accuracy of immunoassays for the detection of antibodies to citrullinated proteins.

Authors:  Nicola Bizzaro; Marilina Tampoia
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

8.  Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis.

Authors:  Hirofumi Shoda; Keishi Fujio; Mihoko Shibuya; Tomohisa Okamura; Shuji Sumitomo; Akiko Okamoto; Tetsuji Sawada; Kazuhiko Yamamoto
Journal:  Arthritis Res Ther       Date:  2011-11-22       Impact factor: 5.156

Review 9.  Validation processes of protein biomarkers in serum--a cross platform comparison.

Authors:  Katja Köhler; Harald Seitz
Journal:  Sensors (Basel)       Date:  2012-09-18       Impact factor: 3.576

10.  Soluble alpha-enolase activates monocytes by CD14-dependent TLR4 signalling pathway and exhibits a dual function.

Authors:  Clément Guillou; Manuel Fréret; Emeline Fondard; Céline Derambure; Gilles Avenel; Marie-Laure Golinski; Mathieu Verdet; Olivier Boyer; Frédérique Caillot; Philippe Musette; Thierry Lequerré; Olivier Vittecoq
Journal:  Sci Rep       Date:  2016-03-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.